Clinical Report: C5orf46 as a Prognostic Biomarker in KIRC and Pan-Cancer
Overview
C5orf46 is identified as a potential oncogene with significant implications for patient survival in various cancers, particularly KIRC and others such as gastrointestinal and gastric cancers. Its upregulation correlates with adverse clinical outcomes and influences tumor microenvironment dynamics.
Background
The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment response. Understanding the molecular mechanisms and biomarkers that influence TME interactions, particularly how C5orf46 modulates these interactions, is essential for developing targeted therapies.
Data Highlights
Key findings indicate that C5orf46 is upregulated in various cancers, particularly KIRC, with implications for patient survival.
Key Findings
C5orf46 is upregulated in various cancers, with the highest expression in KIRC.
Higher C5orf46 expression is associated with worse overall survival and shorter recurrence-free survival.
The expression of C5orf46 is influenced by DNA methylation changes.
C5orf46 correlates with key cancer traits such as angiogenesis, immune infiltration, and ECM degradation.
The gene is linked to the sensitivity of certain chemotherapy drugs.
Clinical Implications
C5orf46 may serve as a novel prognostic biomarker for KIRC and other cancers, aiding in patient stratification and treatment planning. Its role in TME dynamics suggests potential therapeutic targets for enhancing treatment efficacy, warranting further exploration in clinical trials.
Conclusion
C5orf46 represents a significant advancement in understanding cancer biology and prognosis, warranting further investigation as a therapeutic target in clinical settings, particularly in relation to TME interactions.
